EuropaBio Statement on the vote on the ENVI Committee on the revision of the EU General Pharmaceutical Legislation
Date
19 Mar 2024
Sections
InfoSociety
Brussels, 19 March 2024
EuropaBio takes note of today’s vote on the revision of the EU General Pharmaceutical Legislation (GPL) in the European Parliament’s Committee on the Environment, Public Health and Food Safety (ENVI). A supportive and future-proof GPL is essential to ensure Europe can fully benefit from healthcare biotech innovations for patients, society, and economic development.
As the co-legislators continue to progress on this critical legislation, EuropaBio is committed to work with policymakers and all interested parties of the life sciences ecosystem. We remain convinced that by bringing further improvements to the GPL, it can enable Europe to once again be a leader of innovation.
---------------
About EuropaBio
EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life; to prevent, diagnose, treat, and cure diseases; to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members, plus national biotechnology associations and bioregions. Read more about our work at www.europabio.org.